Clinics in Dermatology
Volume 26, Issue 5 , Pages 509-514 , September 2008

Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety

  • Michael P. Schön, MD

      Affiliations

    • Rudolf Virchow Center, Deutsche Forschungsgemeinschaft Research Center for Experimental Biomedicine, Versbacher Str 9, 97078 Würzburg, Germany
    • Department of Dermatology, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
    • Department of Dermatology and Venerology, University Medical Center Göttingen, von-Siebold Str 3, 37075 Göttingen, Germany
    • Corresponding Author InformationDepartment of Dermatology and Venerology, University Medical Center Göttingen, von-Siebold Str 3, 37075 Göttingen, Germany. Tel.: +49 551 39 6401.

References 

  1. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med. 1999;341:1817–1828
  2. Schön MP, Zollner TM, Boehncke WH. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol. 2003;121:951–962
  3. Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–1912
  4. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16:1–4
  5. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60–66
  6. von Andrian UH, Chambers JD, McEvoy LM, Bargatze RF, Arfors KF, Butcher EC. Two-step model of leukocyte-endothelial cell interaction in inflammation: distinct roles for LECAM-1 and the leukocyte beta 2 integrins in vivo. Proc Natl Acad Sci U S A. 1991;88:7538–7542
  7. Feizi T. Carbohydrate ligands for the leukocyte-endothelium adhesion molecules, selectins. Results Probl Cell Differ. 2001;33:201–223
  8. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. Nat Rev Immunol. 2004;4:325–335
  9. Berlin C, Bargatze RF, Campbell JJ, et al. Alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell. 1995;80:413–422
  10. Singbartl K, et al. A CD2-green fluorescence protein-transgenic mouse reveals very late antigen-4–dependent CD8+ lymphocyte rolling in inflamed venules. J Immunol. 2001;166:7520–7526
  11. Schön MP, Ruzicka T. Psoriasis: the plot thickens…. Nat Immunol. 2001;2:91
  12. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med. 2002;8:157–165
  13. vonAndrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med. 2000;343:1020–1034
  14. Grabbe S, Varga G, Beissert S, et al. Beta2 integrins are required for skin homing of primed T cells but not for priming naive T cells. J Clin Invest. 2002;109:183–192
  15. Boehncke WH, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature. 1996;379:777
  16. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878–1887
  17. Schön MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med. 1997;3:183–188
  18. Schön MP. Animal models of psoriasis—what can we learn from them?. J Invest Dermatol. 1999;112:405–410
  19. Nestle FO, Conrad C, Tun-kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005;202:135–143
  20. Boyman O, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor alpha. J. Exp. Med. 2004;199:731–736
  21. Krueger JG, Wolfe J, Nabeya RT, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995;182:2057–2068
  22. Zollner TM, Asadullah K, Schön MP. Targeting leukocyte trafficking to inflamed skin—still an attractive therapeutic approach?. Exp Dermatol. 2007;16:1–12
  23. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol. 2002;46:1–23
  24. Jullien D, Prinz JG, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology. 2004;208:297–306
  25. Schmitt-Rau K, Jahn S. Efalizumab (Raptiva). In:  Dübel S editors. Handbook of therapeutic antibodies. 2007;
  26. Mortensen DL, Wallicke PA, Wang X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol. 2005;45:286–298
  27. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm. 1999;27:397–420
  28. Gottlieb AB, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol. 2000;42:428–435
  29. Coffey GP, Stefanich E, Palmieri S, et al. In vitro internalization, intracellular transport and clearance of efalizumab (Raptiva) by human T cells. J Pharmacol Exp Ther. 2004;310:896–904
  30. Sun Y, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA. Population pharmacokinetics of efalizumab (humanized monoclonal CD11 antibody) following long term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol. 2005;45:468–476
  31. Gottlieb AB, et al. Efficacy, safety, and pharmacokinetic outcomes observed in patients with plaque psoriasis during long-term efalizumab therapy: Results from an open-label trial. In: International Investigative Dermatology Meeting Poster 379 (Miami Beach, Fla). 2003;
  32. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Wallicke PA, Garovoy M. Psoriasis as a model for T-cell–mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol. 2002;138:591–600
  33. Vugmeyster Y, Kiluchi T, Lowes MA, et al. Efalizumab (anti CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol. 2004;113:38–46
  34. Menter A, Griffiths CE. Efalizumab and psoriasis. London: Science Press Ltd; 2004;
  35. Leonardi C, Menter A, Sterry W, Bos JD, Papp K. Long-term management of chronic plaque psoriasis: guidelines for continuous therapy with efalizumab. In: 14th EADV Fall Symposium (London, UK; 12-16 Oct 2005). 2005;
  36. Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003;290:3073–3080
  37. Papp KA, Bressink R, Fretzin S, et al. The safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized controlled trial. Int J Dermatol. 2006;45:605–614
  38. Lebwohl M, Trying SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004–2013
  39. Sterry W, Dubertret L, Papp KA, Chimenti S, Larsen CG. Efalizumab for patients with moderate to severe chronic plaque psoriasis: results of the international, randomized, controlled phase III clinical experience acquired with Raptiva (CLEAR). J Invest Dermatol. 2004;123:A64;[abstract]
  40. Leonardi C, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005;52:425–433
  41. Ring J, Dubertret L, May T, Chimenti S, Sterry W. The safety and efficacy of efalizumab patients with chronic plaque psoriasis. Results from retreatment and extended treatment phases following a placebo-controlled trial. In: 14th EADV Fall Symposium, 12-16 October, 2005 P06.87 (London, UK). 2005;
  42. Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005;141:31–38
  43. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004;3:614–624
  44. Gottlieb AB, Gordon KB, Hamilton TK, Leonardi C. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe plaque psoriasis: final phase IIIb study results. J Am Acad Dermatol. 2005;52:4
  45. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407
  46. Menter A, Kosinski M, Bresnahan BW, Papp K, Ware JE. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo controlled clinical trials of moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2004;3:27–38
  47. Menter A, Kardatzke D, Rundle AC, Garovoy MR, Leonardi C. Incidence and prevention of rebound upon efalizumab discontinuation. In: International Psoriasis Symposium 2004 (Toronto, CDN, 2004). 2004;
  48. Papp K, Toth D, Rosoph L. Investigational study comparing different transitioning therapies for patients discontinuing treatment with efalizumab. In: 14th EADV Fall Symposium (London, UK; 12-16 Oct 2005). 2005;
  49. Pincelli P, Casset-Semanez F. Efalizumab therapy and incidence of arthropathy adverse events: analysis of pooled data from phase II, III, IV clinical trials. In: Psoriasis—from gene to cliic. 4th international congress. (London, UK; 1-3 Dec 2005). 2005;
  50. Serono. Raptiva (efalizumab). Summary of product characteristics. Munich: Serono Ltd; 2004;
  51. Leonardi C. Efalizumab in the treatment of psoriasis. Dermatol Ther. 2004;17:393–400
  52. Langley RG, Carey WP, Rafal ES, et al. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005;27:1317–1328
  53. Leonardi C, Toth D, Cather JC, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204–214
  54. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg. 2005;24:19–27

PII: S0738-081X(07)00250-7

doi: 10.1016/j.clindermatol.2007.10.027

Clinics in Dermatology
Volume 26, Issue 5 , Pages 509-514 , September 2008

Article Tools